RS63360B1 - Upotreba pilokarpin hidrohlorida u lečenju prezbiopije - Google Patents
Upotreba pilokarpin hidrohlorida u lečenju prezbiopijeInfo
- Publication number
- RS63360B1 RS63360B1 RS20220575A RSP20220575A RS63360B1 RS 63360 B1 RS63360 B1 RS 63360B1 RS 20220575 A RS20220575 A RS 20220575A RS P20220575 A RSP20220575 A RS P20220575A RS 63360 B1 RS63360 B1 RS 63360B1
- Authority
- RS
- Serbia
- Prior art keywords
- presbyopia
- treatment
- pilocarpine hydrochloride
- pilocarpine
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662144P | 2018-04-24 | 2018-04-24 | |
US201862780117P | 2018-12-14 | 2018-12-14 | |
US201962790957P | 2019-01-10 | 2019-01-10 | |
EP19729883.9A EP3681500B1 (en) | 2018-04-24 | 2019-04-24 | Use of pilocarpine hydrochloride for the treatment of presbyopia |
PCT/US2019/028917 WO2019209955A2 (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
RS63360B1 true RS63360B1 (sr) | 2022-07-29 |
Family
ID=66821312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20220575A RS63360B1 (sr) | 2018-04-24 | 2019-04-24 | Upotreba pilokarpin hidrohlorida u lečenju prezbiopije |
Country Status (24)
Country | Link |
---|---|
US (3) | US10610518B2 (sr) |
EP (2) | EP3681500B1 (sr) |
JP (3) | JP6946575B2 (sr) |
KR (2) | KR20230079489A (sr) |
CN (1) | CN112272558A (sr) |
AU (3) | AU2019261598B9 (sr) |
BR (1) | BR112020021845A2 (sr) |
CA (2) | CA3162141A1 (sr) |
CL (1) | CL2020002734A1 (sr) |
CO (1) | CO2020014563A2 (sr) |
DK (1) | DK3681500T3 (sr) |
ES (1) | ES2920803T3 (sr) |
HR (1) | HRP20220762T1 (sr) |
HU (1) | HUE058931T2 (sr) |
IL (1) | IL278178A (sr) |
LT (1) | LT3681500T (sr) |
MX (1) | MX2020011301A (sr) |
PH (1) | PH12020551766A1 (sr) |
PL (1) | PL3681500T3 (sr) |
PT (1) | PT3681500T (sr) |
RS (1) | RS63360B1 (sr) |
SG (1) | SG11202010472XA (sr) |
SI (1) | SI3681500T1 (sr) |
WO (1) | WO2019209955A2 (sr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7274475B2 (ja) | 2017-07-20 | 2023-05-16 | セインダ ファーマシューティカル グアンジョウ コーポレイション | 近視の処置のための組成物および方法 |
KR20210096096A (ko) | 2018-10-26 | 2021-08-04 | 오큐파이어 파마, 인크. | 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물 |
AU2021338618B2 (en) * | 2020-09-11 | 2024-02-01 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
JP2024505517A (ja) * | 2021-01-28 | 2024-02-06 | グラウコス コーポレイション | 製剤 |
US20220347170A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | Method of Reducing Brow Ache |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
WO2023125544A1 (zh) * | 2021-12-28 | 2023-07-06 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
US20230263727A1 (en) * | 2022-01-14 | 2023-08-24 | Somerset Therapeutics, Llc | Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods |
US20230248699A1 (en) | 2022-02-09 | 2023-08-10 | Somerset Therapeutics, Llc | Formulations of pilocarpine and brimonidine compounds and related methods |
WO2023205695A1 (en) | 2022-04-21 | 2023-10-26 | Glaukos Corporation | Ophthalmic topical cream compositions |
US20230372303A1 (en) | 2022-05-18 | 2023-11-23 | Glaukos Corporation | Applications of zwitterions in ophthalmic topical cream compositions and preparations |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
JP2536806B2 (ja) | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
AU4653993A (en) | 1992-07-02 | 1994-01-31 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
WO1994010976A1 (en) * | 1992-11-16 | 1994-05-26 | Ciba Vision Ag, Hettlingen | Polyvinyl alcohol/borate ophthalmic drug delivery system |
US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
US5574518A (en) | 1995-01-10 | 1996-11-12 | Les Laboratoires Opti-Centre Inc. | System incorporation two different sphero-non-spherical contact lenses for correcting presbytia |
US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US6291466B1 (en) | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
IT1306135B1 (it) * | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
WO2001019364A1 (en) | 1999-09-16 | 2001-03-22 | Horn Gerald D | A method for optimizing pupil size using alpha antagonist |
TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
EP1328214A4 (en) | 2000-09-20 | 2009-07-29 | Shahinian Lee Jr | NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION |
US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
ITMI20010708A1 (it) | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
US20030139737A1 (en) | 2002-01-24 | 2003-07-24 | J.T. Lin | Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift |
CN1684701B (zh) | 2002-07-30 | 2012-10-17 | 奥默罗斯公司 | 眼科冲洗液及方法 |
US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
JP5583310B2 (ja) | 2002-12-20 | 2014-09-03 | チャクシュ・リサーチ・インコーポレーテッド | 眼球の症状の予防及び治療のための眼科用製剤 |
DK2163643T3 (en) | 2003-03-05 | 2015-03-23 | Halozyme Inc | Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered |
US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
US20070053964A1 (en) | 2004-05-21 | 2007-03-08 | Akiharu Isowaki | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
CA2614519A1 (en) | 2004-10-22 | 2006-05-04 | Omer Yilmaz | System and method for aligning an optic with an axis of an eye |
PL1933833T3 (pl) | 2005-09-02 | 2011-09-30 | Theravida Inc | Terapia do leczenia pęcherza nadreaktywnego |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
JP5215300B2 (ja) | 2006-07-12 | 2013-06-19 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 置換アシルアニリドおよびそれらの使用方法 |
DK1938839T3 (da) | 2006-12-18 | 2009-11-30 | Jorge Luis Benozzi | Oftalmiske sammensætninger af parasympatiske stimulanter og anti-inflammatoriske midler til anvendelse i behandlingen af presbyopi |
WO2009046967A1 (en) | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
AU2015202175A1 (en) | 2007-12-15 | 2015-05-14 | Anant Sharma | Optical correction |
WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
TW201109325A (en) | 2009-07-30 | 2011-03-16 | Wakamoto Pharma Co Ltd | Aqueous composition for eye drops |
AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
MX344046B (es) * | 2011-01-26 | 2016-12-02 | Allergan Inc | Composicion de androgeno para tratar una afeccion oftalmica. |
TR201903465T4 (tr) | 2011-09-20 | 2019-04-22 | Allergan Inc | Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler. |
CA2849192C (en) | 2011-10-12 | 2019-09-24 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
AU2012351948A1 (en) | 2011-12-16 | 2014-07-10 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer |
EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
WO2014121028A1 (en) | 2013-02-01 | 2014-08-07 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
PT2950648T (pt) | 2013-02-01 | 2020-01-06 | Ocuphire Pharma Inc | Soluções oftálmicas aquosas de fentolamina e usos médicos |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
WO2015105144A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
WO2015122853A1 (en) | 2014-02-11 | 2015-08-20 | Vid D.O.O. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
JP2018521000A (ja) | 2015-05-29 | 2018-08-02 | シドネキシス,インク. | D2oで安定化された医薬製剤 |
US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
CH711969A2 (it) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
WO2018033792A2 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
CN115089547A (zh) | 2016-10-12 | 2022-09-23 | Ps治疗有限公司 | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 |
-
2019
- 2019-04-24 EP EP19729883.9A patent/EP3681500B1/en active Active
- 2019-04-24 MX MX2020011301A patent/MX2020011301A/es unknown
- 2019-04-24 KR KR1020237017632A patent/KR20230079489A/ko active Search and Examination
- 2019-04-24 PL PL19729883.9T patent/PL3681500T3/pl unknown
- 2019-04-24 LT LTEPPCT/US2019/028917T patent/LT3681500T/lt unknown
- 2019-04-24 DK DK19729883.9T patent/DK3681500T3/da active
- 2019-04-24 WO PCT/US2019/028917 patent/WO2019209955A2/en active Application Filing
- 2019-04-24 SG SG11202010472XA patent/SG11202010472XA/en unknown
- 2019-04-24 RS RS20220575A patent/RS63360B1/sr unknown
- 2019-04-24 PT PT197298839T patent/PT3681500T/pt unknown
- 2019-04-24 SI SI201930260T patent/SI3681500T1/sl unknown
- 2019-04-24 HU HUE19729883A patent/HUE058931T2/hu unknown
- 2019-04-24 AU AU2019261598A patent/AU2019261598B9/en active Active
- 2019-04-24 CA CA3162141A patent/CA3162141A1/en active Pending
- 2019-04-24 HR HRP20220762TT patent/HRP20220762T1/hr unknown
- 2019-04-24 ES ES19729883T patent/ES2920803T3/es active Active
- 2019-04-24 KR KR1020207033656A patent/KR20210005134A/ko not_active IP Right Cessation
- 2019-04-24 JP JP2020559558A patent/JP6946575B2/ja active Active
- 2019-04-24 BR BR112020021845-6A patent/BR112020021845A2/pt unknown
- 2019-04-24 CA CA3074618A patent/CA3074618C/en active Active
- 2019-04-24 US US16/393,175 patent/US10610518B2/en active Active
- 2019-04-24 CN CN201980037652.3A patent/CN112272558A/zh active Pending
- 2019-04-24 EP EP22160205.5A patent/EP4066830A1/en active Pending
-
2020
- 2020-02-14 US US16/791,039 patent/US11285134B2/en active Active
- 2020-05-21 AU AU2020203311A patent/AU2020203311A1/en not_active Abandoned
- 2020-10-20 IL IL278178A patent/IL278178A/en unknown
- 2020-10-22 CL CL2020002734A patent/CL2020002734A1/es unknown
- 2020-10-23 PH PH12020551766A patent/PH12020551766A1/en unknown
- 2020-11-24 CO CONC2020/0014563A patent/CO2020014563A2/es unknown
-
2021
- 2021-09-15 JP JP2021150116A patent/JP7470667B2/ja active Active
-
2022
- 2022-01-12 US US17/647,813 patent/US20220241245A1/en not_active Abandoned
- 2022-02-18 AU AU2022201106A patent/AU2022201106A1/en not_active Abandoned
-
2024
- 2024-04-08 JP JP2024062082A patent/JP2024096131A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT3681500T (lt) | Pilokarpino hidrochlorido naudojimas presbiopijos gydymui | |
GB201820166D0 (en) | Therapeutic agents | |
GB201820165D0 (en) | Therapeutic agents | |
IL276398A (en) | Combined treatment for mastocytosis | |
IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
IL283948A (en) | Methods for treating depression | |
SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
GB201805816D0 (en) | Therapeutic agents | |
GB201902277D0 (en) | Therapeutic agents | |
IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
IL290756A (en) | Treatment of azoles | |
GB201906804D0 (en) | Therapeutic agents | |
IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
IL283031A (en) | And will grow to treat the symptoms of overactivity in the gland | |
ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
EP3802491C0 (en) | PHOTOCHROMIC COMPOUNDS FOR USE IN THE TREATMENT OF EYE DISORDERS | |
GB201901130D0 (en) | Formulation for the treatment of tendinopathies | |
GB201912760D0 (en) | Treatment | |
GB201912335D0 (en) | Treatment | |
GB201912365D0 (en) | Treatment | |
GB201911816D0 (en) | Treatment | |
GB201911603D0 (en) | Treatment | |
GB201904253D0 (en) | Treatment |